AMANDA CURRY: Open Payments
NPI 1447594924 · ARNOLD, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$952 in 45 payments from 18 companies in 2025. Trend: 2023 $753 · 2024 $754 · 2025 $952
Food & beverage: $952
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $171 |
| PFIZER INC. | 5 | $105 |
| ABBVIE INC. | 5 | $101 |
| Lilly USA, LLC | 6 | $98 |
| AstraZeneca Pharmaceuticals LP | 4 | $84 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $64 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $50 |
| Astellas Pharma US Inc | 2 | $50 |
| Boston Scientific Corporation | 1 | $45 |
| Insulet Corporation | 1 | $33 |
Products named: MOUNJARO, VRAYLAR, Rybelsus, CAPLYTA, XIFAXAN, Veozah, Wegovy, NURTEC ODT.
Industry payments across MD — which companies pay providers there.
